It's a therapeutics evidence feast this month. We start with deprescribing in older adults - Anna Hung, assistant professor at the Duke University School of Medicine has written a summary of the evidence, and we discuss why there are so few trials on an important topic. Metformin is typically first line for type II diabetes, but what should be next? A new cohort study emulating a comparative effectiveness trial has been published, and the team discuss using observational data for this very common problem. Finally, a new trial on nirmaltrevir for covid 19 in those at higher risk of severe disease or those who are unvaccinated. Ā Links BMJ - Deprescribing in older adults with polypharmacy BMJ - Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data NEJM - Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Talk Evidence
Transcribed and ready to explore now
Talk evidence covid-19 update - natural history of covid, include patients in guidelines
09 May 2020
Talk Evidence
Talk Evidence covid-19 update - lack of testing transparency, how to give good debate
04 May 2020
Talk Evidence
Talk Evidence covid-19 update - covid ethics, waste and a minimum RCT size
24 Apr 2020
Talk Evidence
Talk Evidence covid-19 update - Remdesivir, care homes, and death data
17 Apr 2020
Talk Evidence
Talk Evidence covid-19 update - hydroxy/chloroquinine, prognostic models and facemaskss
13 Apr 2020
Talk Evidence
Talk Evidence covid-19 update - pneumonia, guidelines, preprints and testing
09 Apr 2020
Talk Evidence